Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Q-Linea, Audiocast, Q3'25

By Inderes10/20/2025, 11:00 AM
Q-Linea

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Stuart Gander
00:03 - 20:37

Hello everyone. Welcome and thank you for joining this presentation of the Q-linea AB Q3 report. You have Stuart Gander here, President and CEO, and I'm joined by my CFO, Christopher Samuelson. So we'll do this a little bit differently following our traditional process here. Just a quick disclaimer that will be taken as read and understood, moving ahead to the topics for today. So I will start, as usual, with a commercial update. I will share some of the feedback that we're getting from customers in our various interactions and some of the word of mouth that's starting to spread very nicely between customers. I will discuss our priorities for Q4 to close out the year strong before I hand it over to Christopher, who will walk through our financials for the quarter. And, as always, we will reserve time for your questions at the end. All right. And for those who just have a few minutes to join us, here are a few key messages I would like to emphasize and ensure everyone walks away with today. The first point is that the quarter was a strong one regarding consumables. Consumables demand on the instruments. A couple of factors are driving that. Firstly, we had a large number of instruments sold during Q1 and Q2, and one from Q1 was activated during the quarter. Those obviously started to pull through volumes. We continue to see some increases in the same instrument pull-through as customers are getting their protocols finalized and are starting to test on a larger set of their patients. Overall, the commercial pipeline continues to grow very nicely. The US team has expanded their number of customers that they're speaking to, particularly in the front end of the pipeline, where we expect the contracts to come through, is starting to build up. So we've got over a dozen that are either in evaluation, setting up an evaluation currently, or already in contracting. And those obviously have a fairly near-term outlook with strong visibility on the EMEA side of things. Franco and his team have also been busy. Italy continues to build up nicely. We are proceeding with more than ten or so opportunities in Italy. I'll talk a little bit more later on the deal and how we see the country's dynamics evolving there. But more broadly and perhaps even more exciting, the rest of Europe is continuing to build up. Uh, we do expect some contracts outside Italy during the quarter. And we have our first evaluations being planned now in Asia and Latin America. As of now, we are in commercial discussions in over 15 countries, which we're very excited to see. We do expect a strong close to the year. We're pushing hard to close those contracts, especially in North America. It's fairly traditional that institutions do their capital purchase contracting in Q4, or it tends to be back-end weighted. We hope for a strong quarter to close out. Another dynamic that's driving this is that one of the competitors in the field, Accelerate Diagnostics, has informed their customers that they will not be able to support the installed Pheno base of instruments. And that has triggered a number of conversations. Many of those customers were already looking at ASTar, but it's set a timeline somewhat more urgently for many of the customers. So, we're actively working with those players to engage with them. The other news, on the more internal side of things, we're very pleased with the work that Henrik Jacobson and the operations team have done, pulling in all of the activities needed for our in-house production. Uh, so that's now completed and signed off. So going forward, all of our discs will now be fully produced in-house, which significantly decreases the cost of goods per disc on a go-forward basis. And it's good timing because now, as I said, we see the consumables volume starting to pick up. And then finally, we continue to work on reducing operational costs. This is following the stated plan and strategy that we shift our resources towards market-centric activities, getting in front of customers, getting the word of rapid ASTar and ASTar out into the market, and continue to refine and focus our development activities. Now that we're through some of the major efforts to get ASTar ready, we're working on strategic developments for the ASTar platform, but are simultaneously able to continue reducing resources on the back end, so to speak. So we've brought down spending during Q3 and have a plan going forward to take out an additional roughly 10% of the cost base. So with that, maybe just some orientation for those new to Q-linea AB and the AST market. So Q-linea AB manufactures a flagship diagnostic medical instrument called the ASTar. It is the leader. We contend in our field for rapid antimicrobial susceptibility testing. It stands out from the others, notably due to its fully automated random access and continuous access platform, which is very well designed for automated lab workflows. For the modern lab, it has very high clinical reliability, test reproducibility, and a high throughput for labs. It also requires very low hands-on time, which is critical for the busy lab tech in this day and age. Good. So with that, I mean, the journey we're on here. I've presented this before, so I'll just touch on it briefly. But again, for those orienting, this is not per se a new set of testing. Antimicrobial susceptibility testing has been around for a long time. There's an established market. The challenge for the patients and hospitals is that the current standard of care technologies can take several days. 48 to 72 hours to produce an actionable result for the physician. And essentially, the ASTar produces results within six hours. So what we anticipate and are starting to see with the increased demand for our tests, is that for critical patients, testing will move towards the rapid AST systems such as ASTar, obviously starting with blood infections that drive sepsis, being one of the most acute critical patient categories. But there are other critical non-blood infections as well that will move over time. We believe in the transition to rapid AST testing. So, if you run the rough numbers, we see 5 to 7 million tests in our space, and we see pricing holding up in that target range of $120 to $180 per test fairly consistently now. So that generates a market just for the blood testing of $600 to $900 million that we're opening up here and starting to see grow. And on that note, sales development during the quarter did not close as many contracts as we'd hoped. We have now ended with 17 instruments in active routine use. I did mention that we turned on six of the instruments that were sold earlier. So, it's nice to see that the time to installation and go live is continuing to shorten as we anticipated. The contracts we secured were both in the US and Italy. And we do see that there is a strong build-up. As I mentioned earlier, especially in the US, contracts are entering their final stage. So I do expect the quarter to close out strong. We continue to push hard towards our target of 30 instruments for the year. Obviously, before, when we talked about this last quarter, we had in front of us the tender in Italy with nine instruments. So we're openly disappointed, of course, that our previously successful appeal of the tender decision was overturned by a court in Rome. So, whilst there has been no final award of that tender, there may be developments on that front. We now give lower visibility for sure on those nine instruments. So, with that, you know, the upper end of our range last time, 30 to 40, we think is quite unlikely. However, that said, we do have plenty of instruments in the pipeline here that we're working through. So the 30 is within reach on a strong Q4 close here. That's supported by these 15 countries that are now active. Obviously, our direct team in the US and Italy are working hard on their own pipeline of customers. We work through a network of distributors and agents in other countries around the world, and Franco has been leading many of those efforts. And what we see here now is conversations we've had earlier starting to warm up. And distributors are coming to Q-linea AB with customer-specific cases and evaluations that they want to run. So our posture on geographic expansion has been a measured one to conserve resources and be very thoughtful about where we put time and energy. Uh, so we're directing both towards areas where antimicrobial resistance is particularly high, i.e. There's strong clinical need, but also there's a clear willingness to pay and a flagship customer willing to adopt in the market. In my experience, once the top institutions in any given country adopt, you start to get a rethinking of the standard of care. And from there, let's say the proverbial snowball starts to roll. So our approach now is to work with distributors to identify those flagship institutions and invest in a very targeted way with our partners into those relationships to then grow in the market. I hope to see that during Q4, instruments will be distributed to more markets, setting up for evaluations that will convert in the early part of next year. On that note, we have already shipped to Saudi Arabia. That's the third evaluation ongoing in the Middle East with our partner Ameco, which has built a very robust pipeline in that region. Expect to see that 2026 will be a strong year. We are now represented in the United Arab Emirates, Kuwait, and Saudi Arabia. Obviously, these are three of the cornerstone markets for that region, which tend to set standards. I think that bodes well for the outlook. I already spoke about the US pipeline. I would say one dynamic there is that, obviously, Accelerate had a fairly robust installed base of customers that are now accustomed to using rapid AST and seeing the clinical benefits of it. And those customers can no longer be served with consumables. They've turned to Q-linea AB for an alternative. So we're working with several of them now on an accelerated contracting process. As I've talked about several times, it can sometimes be a bit of a convoluted process in the US with large institutions. Given the clinical urgency to maintain patient care, we're optimistic that some of these will move through more quickly, which is good. So those are the highlights for the quarter. And, you know, obviously, the substance, let's say, for how we maintain that target of 30 to close out the year. The team also keeps working at the opening end of the funnel, engaging with customers directly. One of our best avenues to do so remains the face-to-face interaction at conferences, where dozens or even hundreds of customers are accessible, and we can have rich conversations and demonstrate the instrument. Several of these take place over the summer season in the US, with the largest being ADLM in Chicago, where I was present, and the team also represented us at regional shows in Texas and New England. I was also present with the team in Birmingham, UK, for the biannual IBMS conference, where we joined our distributor, Prolab, to catch up with customers there. The general theme of these is very consistent. We continue to publish materials in the space. That's what these conferences are about, and why customers attend them. They want to see the latest science. We want to make sure that Q-linea AB is seen at the forefront of that. The data continues to reinforce the evidence we've demonstrated before regarding the clinical impact of the ASTar in practice, and that body of evidence continues to build. In parallel, our clinical affairs team has been engaging closely with pharmaceutical manufacturers in our industry, particularly those who produce the antibiotics on our panel, which will be used to treat patients. And for us, this represents one of the trickier parts of the development process. There's obviously some cost there, but just getting those formulations ready and stable takes time and specific expertise. We are very pleased that we've now signed development partnerships with three of them. They will help us with some of the raw materials for that and notably support in developing those formulations. This reduction in time and cost helps us to bring new drugs to market on what we internally call our V3 menu. We are also very pleased to present the results from our work together this year, showcasing an ultra-rapid workflow. The direct-from-blood approach. If you recall, the slide I showed earlier is considered the holy grail for our industry. Direct from blood testing, cutting out the need to incubate the blood culture. So, another 10 or 12 hours. And the results there were very strong. Obviously, plenty of work remains to be done for developing a commercial product. We're pleased with the work with the team. And the results continue to show that ASTar delivers effectively as part of the workflow. So, you know, on that note of demonstrating the science and listening to the customer, just put one example here. Several presentations were also made at US conferences by our US customers. But as I mentioned, I was over in Birmingham at the IBMS, and one of our customers, Jennifer Monkhouse, presented data from her lab very nicely. It's one where we've seen an increase in usage as this data has demonstrated that the NHS has, perhaps, an appropriately conservative approach to adopting new technologies. They want to see that the clinical evidence is there. So the lab started using ASTar and has now been able to demonstrate the impact as shown here. I've gotten the nod from their local trust to go ahead and make that available for patients across the system. And there isn't anything, let's say, especially surprising about the numbers here because we keep showing something very similar, but nonetheless, a huge tribute to Jennifer for the great work pulling this together. It reinforces the reduction of time to patient therapy in this case, by around 1.77 days, and every hour counts in sepsis, as we know. And then also the team has made an estimate here on what they determined to be the savings for the trust of €2 million and £2 million. In parallel, our clinical affairs team has been closely engaging with pharmaceutical manufacturing partners in our industry, particularly those who produce the antibiotics that are on our panel and for which patients will be treated. And I think that's a very important point to highlight since the main constraint for many of the clinicians and labs eager to adopt rapid AST is that the healthcare budget holders are trying to find ways to fund new technologies, and therefore, scrutinizing and showing that health economic case is important. This is another data point for us in what we call our business impact model that we discuss with customers every day. It's a tool that we show to help a hospital see the clinical and economic impact in their facility. But, you know, it's one thing taking it from us. It's another matter when a customer shows it to their own stakeholders and peers in the field, which carries even more weight. It's great to see these coming out. More of these continue to come. Basically every quarter. So our attention is now really focused here to close strong on 2025. Highlighting three areas, obviously starting with the commercial side, the conversion of the pipeline that I mentioned, the drive to 30 ASTar in the field, is partly, but not entirely, supported by the additional Pheno users that are reaching out to us. And if we can get those through on a slightly fast-tracked approach. I mentioned the first evaluations in Asia and Latin America. These are somewhat more distant markets geographically. Some, perhaps with some language and training challenges, will need to work through. So, it's a test for our team that's ready and has been preparing for this. So, we'll get some of those going. And then really continuing to drive that consumables pull-through growth on the platform. Obviously, the new installations will achieve that on their own, let's say. But we work closely with customers to discuss with them why and if they stratify customers. Unfortunately, budgets don't allow all customers to use the test for all patients, which is a difficult choice to make in a clinical environment for critical patients. So we work with the customers and try to get them more data so that they can work on that with their stakeholders. So we will continue to do that. This ties into the clinical priorities where our team is focused on those frontline customers. At the same time, we are completing some strategic efforts mentioned earlier, and we're very happy that our internal work is now completed for the version two menu. So we're ready to submit, waiting for the US government to reopen here. And we'll hit send more or less right away. And then the work is being presented at IDWeek in Atlanta. I'm actually in Atlanta as I speak here, where we will present the results from using ASTar as a multi-prep workflow tool, which has benefits in both cost and also operator time, and potentially even reliability of preparing things for the end-to-end test. Very excited about that. That provides another avenue for value for our customers. We're also working to prepare the first publication of results for non-blood AST testing with our research partners. So, there's more to come. We keep alluding to that side of the patient population, since they're potentially even more numerous than blood patients. So we expect to see that having an impact on our business in the very near future. And then on the financial side, I'll turn it over here to Krista to talk through the details. But you know, our commitment is to continue to refine the cost base as we become more efficient in our operations. We have achieved some scale here now so we're able to gain efficiencies. We will work on a couple of key initiatives, such as moving the entire team to our factory location in Uppsala. We currently have two offices in the Uppsala region, so that will generate some savings. Also, I think reducing some of the geographic frictions in the local team there makes us even more efficient. And then some of the external costs as well will continue to decrease both through efficiencies and as projects wind down and we complete those. We are targeting a 10% reduction through 2026, which still gives us the resources we need to drive the commercial agenda and deliver on those strategic projects. Finally, I think Krista will touch on completing the rights issue that we've announced for Q4. So with that, Krista, I will turn it over to you before coming back for questions.

Christopher Samuelson
20:38 - 28:04

And then on the financial side, I'll turn it over to Krista to talk through the details. Stuart, I'll provide you with a financial update and start with the top-line revenues. It's great to see that the recurring income has grown, and we had a record month in September, although from fairly low numbers. We see a 370% increase when comparing the nine months in 2025 with the nine months in 2024, which is obviously good, but from low numbers. But we are on that growth curve now, and we can see that, which makes us happy. Switching to the OpEx side, as Stewart said, the focus is on efficiency. The focus is on bringing the opex down. We are confident that we will achieve this. We are targeting a 10% reduction from the current rate we have now, which is about 13 million per month. So that is what we can see in 2026 and going forward. On the financing side, as Stewart said, we will get to the rights issue. But before that, there are a few things that have happened during the third quarter. We had a reverse share split of 1,000 to 1. That means that the number of shares has decreased by dividing the actual numbers we had before by 1000. So the current number is 6.6. 4 million shares. We have also conducted a reduction of share capital, which was concluded in July. We now have a share capital of 643,000. And the quota value is 0.1 krona. And we have also submitted two new grant applications to the EU. I will touch upon that a bit later. Continue with the OpEx development. As I said, the OpEx has come down. There is a decrease, and we can see that during the third quarter. Obviously, if you look at the number of employees' development from Q1 2024 onwards, we have gone from 126 down to 83. And if you look even further back into 2023, we were up at 150 employees. So we have come down a fair bit, which obviously affects the OpEx, the personnel expenses. But as you said, there are also some major R&D projects that have come to an end which affect the other external costs, helping us to further reduce the OpEx and achieve at least a 10% reduction by 2026. We have some events coming up linked to the rights issue. There is a fairly hectic period now. Tomorrow we will have an extra general meeting held in Uppsala. So, I think we have some participants who may even attend in person. Otherwise, they will not attend. Normally, there are not so many that come to this, but it will be held at Lindell's office in Uppsala, or the legal partner will also attend tomorrow. There's a last day of trading in the company shares with the right to receive subscription rights. And on Wednesday, there will be a prospectus published by us. And also on Wednesday, it is the first day of trading in the shares. Without the subscription rights. Then you can trade in the subscription rights between October 27th to November 5th. The subscription period for this rights issue starts on October 27th and ends on November 10th. We aim to present the outcome around the 11th of November for this rights issue. The rights issue, if I start on that one, is gross 322 million. If 100% is subscribed. We now have 85.6% guaranteed or covered by subscription rights. And if you start with cash at hand at the end of September, 42.6 million, and then you add the guaranteed amount of 220 million, you will reach 262 million. That is, you can call it secured if we get 100%, which we obviously aim for, you will get 266 million with 100%. And together with the existing cash, you will be north of 300 million in secured financing. And then as I said, we have the spending going forward. With the 11.3 to 11.8, there's a span here. If you go down a little bit further on the slide, obviously, this is the spend we have. If we don't sell anything, and we will sell, obviously. And we will get some gross profit from this sale. So, you can do your own math on these things. Additional sources of financing. We are applying for grants where we see fit. We have done a couple of good applications in the third quarter, and we are waiting eagerly to see the outcome of these. One of them has a hybrid financing part, but that is more technical. So there's a grant component in that one. Or. And then there's an investment component included. Then we are looking for working capital financing as well. And we are in discussions with Swedish banks, supported by other entities to offset the risk. That would be really good when we grow with our business model. The reagent rental model, where we place the instrument with the client and get paid when they purchase the consumables, will increase the assets on our balance sheet and will require some financing. And the gross profit, as I indicated before, will increase quarter by quarter. We have this reagent rental model, and when we put new instruments out, that will generate some recurring income and that will grow quarter by quarter. Just to reiterate a little bit on the OpEx, the 30 million we see now or a little bit below that will be for this year. Next year we will be between 11.3 to 11.8 million per month. The working capital has not increased this year. But it will go up next year. That will align with the placement of instruments. That's how it works. The investment in fixed assets has been low this year. It will increase next year when we see the volume come and we have to invest in automated production units. And finally, a statement from the board, which is obviously clear now that we have the rights secured at 85% or more, confirming that we have going concern status, which means that we have the necessary liquidity to cover operations for the next 12 months. So I hand over to you.

Stuart Gander
28:07 - 28:09

Thank you, Christer. It is back to questions then.

Christopher Samuelson
28:11 - 28:13

I think I saw in the presentation.

Operator
28:13 - 28:24

If you wish to ask a question, please dial the pound key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key on your telephone keypad.

Stuart Gander
28:35 - 28:36

Mr. . Why don't you?

Operator
28:36 - 28:41

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad.

Christopher Samuelson
28:44 - 29:06

Unless we have some phone questions, I can step into the activity feed and take questions from the written submissions. So, Stuart, this is one for you. The 30 to 40 machines that we have mentioned before, will that happen? What happens? Why? That's a question from a listener.

Stuart Gander
29:06 - 30:18

Yeah, it's a great question. We obviously targeted a number to close out the year. We know the 30 to 40 range was fairly broad. Acknowledging that the ASTar tender in Italy included nine instruments, we had expected to secure it, to be honest, but I couldn't count on it. So, the upper end of that range was an ASTar, and the lower end was hedging the E star placement, so we're still pushing for it. Obviously, in Q3, we hoped to close some of the contracts that we can see and are actively working on to exceed 20, and we're confident many of those will come in the short term, and the pipeline remains very robust. So I know there are questions, let's say, on whether these customers are converting? Are they selling? Where are the results? But we are seeing it in the field, and it's taking some time to get the contracts written. But, you know, we'll come back to that at the end of the quarter here, but the 30 is the number to chase for and drive for the entire Q-linea AB team.

Christopher Samuelson
30:20 - 30:40

Great. There's a question on the EU financing tender for 400 machines. And the question is, has Q-linea AB participated, or is Q-linea AB participating in, and have we managed step one? And if it's the one I think it is. Yes, we have managed step one, and we are participating in that EU tender process.

Stuart Gander
30:41 - 30:49

Yes, yes. I assume it's referring to the call. . Since you mentioned the 400 instruments. So yes, we have been accepted past the first stage.

Christopher Samuelson
30:50 - 30:55

And there is a question on the Accelerate Diagnostics systems. Where do you see that one? Can you take that one?

Stuart Gander
30:55 - 32:32

Yeah, I see that. It's now. Yeah. Good question. So the question is, how many Accelerate Diagnostics Pheno systems are in the market today? Are all of these active and addressable? So it's a good question. Obviously, we don't have perfect insight into our competitors' installed base. I mean, there have been various reports, and I think the general industry assessment is that they may have distributed up to 300 instruments. Uh, that wouldn't correspond to the same number of hospitals. The design of the Pheno is such that it's one test, one instrument. Thus. So, there could be several Pheno systems per hospital. We know that to be the case in instances where we observe it. So, you know, I think a safe figure might be something between 80 and 100 customers active in some way. Obviously, you know, given that platform, not all of those would be at a high level of activity. So when you talk about addressable for Q-linea AB, it's a great question. We would say that there are at least several dozen. And there is a question on the Accelerate Diagnostics systems. We have visibility on a good number of those already on both sides of the Atlantic, in the US and Europe, and obviously need to work through with the customers to convert. I can say that we've already seen situations where we consolidate several Pheno instruments into one ASTar, given the automation capability of an ASTar instrument. So it won't be a one-to-one. But we work at the level of the hospital and the lab, so there's definitely dozens at this stage that we're targeting.

Christopher Samuelson
32:32 - 33:03

Chasing another question on. Yes, we have applied, and we have successfully managed to complete step one, now moving into step two. So yeah, I think we have answered that one already. And then another question on whether Q-linea AB has got answers or not from the new V2 panel. And if we have customers that are ready, if the FDA gives an okay for version two of our panel, we are prepared to proceed.

Stuart Gander
33:04 - 34:44

Great question. The quick answer to that is yes, absolutely. We in the US are actively grouping our customers into essentially three groups: one that is ready to go directly with ASTar today, some of whom will just use the menu as is. Others will validate on their own the remaining tests under LTT. So that's category one. Obviously, they're pushing to close. A large body of customers has tried the ASTar or looked at it and have told us that they want to take it up when version two menu is available. The reason for that basically boils down to there are a couple of drugs in the US standard of care that they want to see results for, which we have on our EO panel. So they know those drugs work. They can see the data from our EU studies. They're sort of happy to wait, let's say. So they don't have to do the LTT. We categorize those customers to follow up on during Q1 of next year, as we anticipate the FDA process should take, we estimate, around six months. It can be anything from 90 days to 180 days after submission. So that will definitely have an effect. And then the third category, to close it off, are those who say they're still thinking about rapid AST but don't have a budget now, so we keep them on the list to follow up later. That's a large group of hospitals that are continuing to work on their budgeting and getting the resources to put in place. There's more than enough customers in the first two buckets to meet our targets for both this year and next year.

Christopher Samuelson
34:46 - 34:50

Right. And we have another question on the 30 contracts. I think you have addressed that one, Stuart.

Stuart Gander
34:50 - 34:54

Yeah, sure. And if we have customers that are ready, if the FDA gives an okay for version two of our panel. It's just a question of timing, right?

Christopher Samuelson
34:54 - 34:55

Yeah.

Stuart Gander
34:56 - 34:58

When do we get these over the line? Absolutely.

Christopher Samuelson
34:58 - 35:06

And then there is a question on the timeline for enabling ASTar for isolates and lookalikes. Right.

Stuart Gander
35:07 - 36:00

Yes. So, great question. I referenced that in terms of our publications. So we're working on data with users in the field to put that together. We expect publications during next year that will obviously help. The ASTar platform is approved for use with blood testing. This is something intended for research purposes and for customers. That said, there's high demand for that. So we do expect that this will have an impact on our business during next year. It's been hard to quantify just given that if it was fully adoptable by all customers and routine use off the bat as our blood test is, then it would be easier to predict the volumes. Uh, so I can't say exactly what it would be, but I don't think it will be insignificant, even during next year.

Christopher Samuelson
36:01 - 36:13

Right. We have, so far, a final question regarding the risks of a delay in the FDA process. Step one, maybe you can address the risk if there's a delay.

Stuart Gander
36:15 - 38:00

Yes. So, I mean, good question. Very material. The US government, unless something happened very recently, remains closed. So we cannot submit to the FDA, nor can anyone. Despite that, the industry pays its own fees and handles these processes independently. It's a bit frustrating, but they cannot take new applications. Uh, we will be ready to hit send as soon as that opens. To receive applications. Beyond that, the risk of delay is limited because, as I mentioned, there is a time limit on the decision, so there's a limit to how long it can be. Uh, but we would expect that the review will be somewhat shorter this time. First of all, it doesn't contain the instrument itself. It's only a menu update. So that reduces the amount of work and uncertainties, which is great. They've clearly already reviewed the ASTar and the data. So we're basically improving or presenting more data for combinations that they've already seen. So we think it's quite robust. And we have, obviously, in our pre-submission dialogue with the FDA, received input on what to show them to make them confident we can proceed. We've now collected that data. I can't say too much for obvious reasons, but we remain very confident in version two. Menu. Not to prejudice an FDA full review, but from what we see, we don't see a major concern at that level. So it's just down to the process with the FDA, and if there are any more delays in the US government, I would say at this stage, that's a concern.

Christopher Samuelson
38:01 - 38:12

I think so far we have one last question which links to the FDA and version two menu. What share of the pipeline is awaiting V2 clearance? Can we say anything about that?

Stuart Gander
38:14 - 38:49

Yeah, it's probably not far off to say that there's sort of at least half of the customers that we're engaged with are saying, you know, we're going to wait with a quarter being in the first bucket. It's not far off to say that there's at least half of the customers we're engaged with who are saying, you know, we're going to wait, with a quarter being in the first bucket. We're kind of ready to go and so on. The big chunk of customers is saying they want to wait for V2, and then, you know, there's a group that is in that third bucket. So it's a significant number. I mean, mainly because they don't have to do the LTT evaluation. So, yeah, it's the majority.

Christopher Samuelson
38:52 - 39:07

Great. No more questions in the activity feed. So I think that's it, Stuart.

Stuart Gander
39:08 - 39:20

So we think it's quite robust. Well, thanks everyone for joining. Thank you for the questions. Excellent questions. And we'll look forward to coming back in Q4 on that pipeline and our commitment to getting to 30 here.

Christopher Samuelson
39:22 - 39:22

Thank you.

Stuart Gander
39:23 - 39:23

Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…